Aslan Fred sold $260K of ARTV
Aslan Fred (Chief Executive Officer) sold 62,178 shares of Artiva Biotherapeutics, Inc. (ARTV) at $4.18 ($0.26M total) on 2026-11-02.
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure but modest in size, offering limited trading impetus.
Market read
A small insider sale with limited market impact; traders may monitor for any follow‑up activity.
What to watch
The CEO retains a large stake (over 1.4M shares), indicating continued confidence.
Background
Form 4 filing disclosed the CEO's open‑market sale of ARTV shares.
Ticker impact
CEO Aslan Fred sold 62,178 shares for $259,972, reducing his stake to 1,457,428 shares.
likely modest downward pressure as the market prices the insider sell
Insider sales by a CEO can be viewed negatively, but the amount ($260K) is relatively small for a mid‑cap biotech, limiting impact.
Market effects
Minimal effect on the broader biotech sector; similar insider sales are common.
None
None
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- companyArtiva Biotherapeutics, Inc.
Biotech firm listed on NASDAQ under ARTV.
- personAslan Fred
Chief Executive Officer of Artiva Biotherapeutics.



